IgA, IgM, and IgG Antibodies and Neutralizing Activity against SARS-CoV-2 in a Population of Colombian Healthcare Workers and Hospital Staff

Anticuerpos IgA, IgM e IgG y actividad neutralizante frente al SARS-CoV-2 en una población de trabajadores de la salud y personal hospitalario colombiano

Published 2025-04-01

Open | Download
HTML Icon XML Icon PDF Icon Flip Icon
Issue
Vol. 7 No. 2 (2025)
Section
Research Article
How to Cite
1.
Serrano Díaz NC, Colmenares-Mejía CC, Quintero-Lesmes DC, Salazar Acosta I, Suárez Suárez DP, Serrano-García AY, et al. IgA, IgM, and IgG Antibodies and Neutralizing Activity against SARS-CoV-2 in a Population of Colombian Healthcare Workers and Hospital Staff. Rev. Investig. Innov. Cienc. Salud [Internet]. 2025 Apr. 1 [cited 2025 May 25];7(2):1-19. Available from: https://riics.info/index.php/RCMC/article/view/367
DOI

https://doi.org/10.46634/riics.367
Dimensions
PlumX
license
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Norma Cecilia Serrano Díaz
Fundación Cardiovascular de Colombia image/svg+xml
Roles:  
Perfil Google Scholar
https://orcid.org/0000-0003-3532-2002
Claudia Carolina Colmenares-Mejía
Fundación Cardiovascular de Colombia image/svg+xml
Roles:  
Perfil Google Scholar
https://orcid.org/0000-0003-1847-4282
Doris Cristina Quintero-Lesmes
Fundación Cardiovascular de Colombia image/svg+xml
Roles:  
Perfil Google Scholar
https://orcid.org/0000-0001-8875-0110
Isail Salazar Acosta
Fundación Cardiovascular de Colombia image/svg+xml
Roles:  
Perfil Google Scholar
https://orcid.org/0000-0002-9638-3952
Diana Paola Suárez Suárez
Fundación Cardiovascular de Colombia image/svg+xml
Roles:  
https://orcid.org/0000-0003-4273-5067
Show authors biography

Norma Cecilia Serrano Díaz,

Fundación Cardiovascular de Colombia; Floridablanca; Santander; Colombia.

Claudia Carolina Colmenares-Mejía,

Fundación Cardiovascular de Colombia; Floridablanca; Santander; Colombia.

Doris Cristina Quintero-Lesmes,

Fundación Cardiovascular de Colombia; Floridablanca; Santander; Colombia.

Isail Salazar Acosta,

Fundación Cardiovascular de Colombia; Floridablanca; Santander; Colombia.

Diana Paola Suárez Suárez,

Fundación Cardiovascular de Colombia; Floridablanca; Santander; Colombia.

Angie Yarlady Serrano-García,

Fundación Cardiovascular de Colombia; Floridablanca; Santander; Colombia.

Olga Lucía Sopó-Rincón,

Fundación Cardiovascular de Colombia; Floridablanca; Santander; Colombia.

Ligia Stella Meneses Duarte,

Fundación Cardiovascular de Colombia; Floridablanca; Santander; Colombia.

Bladimiro Rincón Orozco,

Escuela de Medicina; Universidad Industrial de Santander; Bucaramanga; Santander; Colombia.

Introduction. During viral infections, the body produces binding antibodies (n-NAbs) and neutralizing antibodies (NAbs). NAbs prevent viral infection of host cells. Since COVID-19's onset in 2020, vaccine research has focused on eliciting high NAb levels.

Objective. To evaluate IgA, IgM, and IgG levels in Colombian healthcare workers and compare NAb test results from DIA.PRO and CPAS.

Method. A cross-sectional study in Bucaramanga, Colombia, collected samples from healthcare workers in June-July and November 2021. Data was gathered via an online survey and blood samples. Antibody levels were measured with AESKULISA® kits, and neutralizing activity was assessed using DIA.PRO and cPass kits. Statistical analyses used Wilcoxon tests and Pearson correlation.

Results. Eighty participants were initially assessed, with forty-seven re-evaluated. Most were women who had received the BioNTech-Pfizer vaccine. Antibody levels declined over time; IgA and IgM were lower in the second sampling, while IgG remained high. Prior COVID-19 infection correlated with higher antibody levels. DIA.PRO and CPAS tests showed strong agreement, with excellent neutralizing reactivity in most participants.

Conclusion. Neutralizing antibody levels against SARS-CoV-2 decrease but remain effective in most healthcare workers, supporting BNT162b2 vaccine efficacy. Further research is needed on emerging variants and neutralizing antibodies in COVID-19 management.

Article visits 165 | PDF visits 123

  1. Ministerio de salud y protección social. Anexo Técnico No 1 (Elaborado con base en el Anexo No.1 “Manual para la elaboración de textos normativos-proyectos de decreto y resolución”, adoptado mediante Decreto 1081 de 2015, modificado por Decreto 1609 del mismo año) [Internet]; 2024 [cited 2024 Dec 24]. Available from: https://www.minsalud.gov.co/Anexos_Normatividad_Nuevo/Memoria-justificativa-281420240919120016734.pdf
  2. Cheedarla N, Hanna LE. Functional and Protective Role of Neutralizing Antibodies (NAbs) Against Viral Infections. In: Buddolla V, editor. Recent Developments in Applied Microbiology and Biochemistry [Internet]. Cambridge: Academic Press; 2019. p. 83-93. doi: https://doi.org/10.1016/B978-0-12-816328-3.00007-6 DOI: https://doi.org/10.1016/B978-0-12-816328-3.00007-6
  3. Beltrán-Pavez C, Riquelme-Barrios S, Oyarzún-Arrau A, Gaete-Argel A, González-Stegmaier R, Cereceda-Solis K, et al. Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile. Sci Adv [Internet]. 2021;7(7):1-13. doi: https://doi.org/10.1126/sciadv.abe6855 DOI: https://doi.org/10.1126/sciadv.abe6855
  4. Li X, Liang C, Xiao X. SARS-CoV-2 Neutralizing Antibody Levels Post COVID-19 Vaccination Based on ELISA Method—A Small Real-World Sample Exploration. Vaccines [Internet]. 2021;9(10):1-10. doi: https://doi.org/10.3390/VACCINES9101139 DOI: https://doi.org/10.3390/vaccines9101139
  5. Lustig Y, Sapir E, Regev-Yochay G, Cohen C, Fluss R, Olmer L, et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lancet Respir Med [Internet]. 2021;9(9):999-1009. doi: https://doi.org/10.1016/S2213-2600(21)00220-4 DOI: https://doi.org/10.1016/S2213-2600(21)00220-4
  6. Carrillo J, Izquierdo-Useros N, Ávila-Nieto C, Pradenas E, Clotet B, Blanco J. Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. Biochem Biophys Res Commun [Internet]. 2021;538:187-91. doi: https://doi.org/10.1016/J.BBRC.2020.10.108 DOI: https://doi.org/10.1016/j.bbrc.2020.10.108
  7. Pang NYL, Pang ASR, Chow VT, Wang DY. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice. Mil Med Res [Internet]. 2021;8(1):1-17. doi: https://doi.org/10.1186/S40779-021-00342-3 DOI: https://doi.org/10.1186/s40779-021-00342-3
  8. Legros V, Denolly S, Vogrig M, Boson B, Siret E, Rigaill J, et al. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell Mol Immunol [Internet]. 2021;18(2):318-27. doi: https://doi.org/10.1038/s41423-020-00588-2 DOI: https://doi.org/10.1038/s41423-020-00588-2
  9. Edara VV, Hudson WH, Xie X, Ahmed R, Suthar MS. Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination. JAMA [Internet]. 2021;325(18):1896-8. doi: https://doi.org/10.1001/JAMA.2021.4388 DOI: https://doi.org/10.1001/jama.2021.4388
  10. Shrestha LB, Tedla N, Bull RA. Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants. Front Immunol [Internet]. 2021;12:752003. doi: https://doi.org/10.3389/FIMMU.2021.752003 DOI: https://doi.org/10.3389/fimmu.2021.752003
  11. Sharun K, Tiwari R, Dhama K, Emran TB, Rabaan AA, Mutair AA. Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies. Hum Vaccin Immunother [Internet]. 2021;17(10):3491-4. doi: https://doi.org/10.1080/21645515.2021.1923350 DOI: https://doi.org/10.1080/21645515.2021.1923350
  12. Furukawa K, Tjan LH, Kurahashi Y, Sutandhio S, Nishimura M, Arii J, et al. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine. JAMA Netw Open [Internet]. 2022;5(5):e2210780. doi: https://doi.org/10.1001/JAMANETWORKOPEN.2022.10780 DOI: https://doi.org/10.1001/jamanetworkopen.2022.10780
  13. Centers for Disease Control and Prevention [Internet]. Atlanta: Centers for Disease Control and Prevention; c2024. SARS-CoV-2 Variant Classifications and Definitions; 2022 Apr 26 [cited 2022 Aug 22]; [about 12 screens]. Available from: https://web.archive.org/web/20220822222151/https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html
  14. Harris PA, Taylor R, Minor BL, Elliot V, Fernandez M, O’ Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform [Internet]. 2019;95:103208. doi: https://doi.org/10.1016/j.jbi.2019.103208 DOI: https://doi.org/10.1016/j.jbi.2019.103208
  15. Colmenares-Mejía CC, Quintero-Lesmes DC, Salazar Acosta I, Suárez DP, Meneses L, Sopó Rincón OL, et al. Seroprevalence of SARS-CoV-2 Infection among Vaccinated Health Workers and Hospital Staff. Arch Clin Biomed Res [Internet]. 2022;6(2):290-5. doi: https://doi.org/10.26502/acbr.50170244 DOI: https://doi.org/10.26502/acbr.50170244
  16. Serrano NC, Quintero-Lesmes DC, Colmenares-Mejía CC, Salazar Acosta I, Suárez DP, Meneses L, et al. Infección por SARS-CoV-2 y respuesta de anticuerpos a la vacuna BNT162b2 en trabajadores de la salud de primera línea de atención para covid-19. Medicina (B Aires) [Internet]. 2022;44(1):31-9. doi: https://doi.org/10.56050/01205498.1659 DOI: https://doi.org/10.56050/01205498.1659
  17. AESKU.GROUP. WE TAKE CARE OF YOUR HEALTH [Internet]. Wendelsheim: Aesku Group; c2024 [cited 2022 Aug 22]; [about 2 screens]. Available from: https://www.aesku.com/
  18. DIA.PRO Diagnostic Bioprobes srl. ACE2-RBD Neutralization Assay – ELISA [Internet]. Sesto San Giovanni: Dia.Pro; c2024 [cited 2022 Aug 22]; [about 2 screens]. Available from: https://www.diapro.it/products/ace2-rbd-neutralization-assay-elisa/
  19. Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of antibody immunity to SARS-CoV-2. Nature [Internet]. 2021;591(7851):639-44. doi: https://doi.org/10.1038/s41586-021-03207-w DOI: https://doi.org/10.1038/s41586-021-03207-w
  20. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med [Internet]. 2021;27(7):1205-11. doi: https://doi.org/10.1038/s41591-021-01377-8 DOI: https://doi.org/10.1038/s41591-021-01377-8
  21. Rogliani P, Chetta A, Cazzola M, Calzetta L. SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines [Internet]. 2021;9(3):1-18. doi: https://doi.org/10.3390/VACCINES9030227 DOI: https://doi.org/10.3390/vaccines9030227
  22. Tea F, Stella AO, Aggarwal A, Darley DR, Pilli D, Vitale D, et al. SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants. PLoS Med [Internet]. 2021;18(7):e1003656. doi: https://doi.org/10.1371/JOURNAL.PMED.1003656 DOI: https://doi.org/10.1371/journal.pmed.1003656
  23. Tang MS, Case JB, Franks CE, Chen RE, Anderson NW, Henderson JP, et al. Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays. Clin Chem [Internet]. 2020;66(12):1538-47. doi: https://doi.org/10.1093/CLINCHEM/HVAA211 DOI: https://doi.org/10.1093/clinchem/hvaa211
  24. Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claër L, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med [Internet]. 2021;13(577): eabd2223. doi: https://doi.org/10.1126/scitranslmed.abd2223 DOI: https://doi.org/10.1126/scitranslmed.abd2223
  25. Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection in humans. Nat Microbiol [Internet]. 2020;5(12):1598-607. doi: https://doi.org/10.1038/s41564-020-00813-8 DOI: https://doi.org/10.1038/s41564-020-00813-8
Publish with RIICS

Scimago

Most read in the last 30 days

Sistema OJS 3.4.0.7 - Metabiblioteca |